Prolonged benefit in the treatment of chronic idiopathic urticaria with astemizole.
A double-blind clinical trial of 51 patients with chronic idiopathic urticaria using oral astemizole for 8 weeks demonstrated significant improvement in symptoms and lesions in 75% of treated patients versus 20% in the placebo group. The suppression of urticaria persisted for an average of 38 days, demonstrating the long duration of action of astemizole.
Honsinger
R W
RW
Department of Medicine, University of New Mexico School of Medicine.
Thomsen
R J
RJ
D016589:Astemizole; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D013997:Time Factors; D014581:Urticaria / Q000188:drug therapy* / Q000473:pathology
D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D016589:Astemizole